Medication-Assisted Treatment (MAT) in Charlotte, NC
Medication-assisted treatment has become one of the most evidence-backed approaches to opioid and alcohol use disorders available in Charlotte. MAT combines FDA-approved medications with behavioral therapy and counseling to treat substance use disorders as the chronic medical conditions they are. In 2024, Mecklenburg County experienced over 270 fatal overdoses—the vast majority involving synthetic opioids—and expanding access to MAT within inpatient settings is one of the most effective tools available for reducing that number. For individuals whose brains have been fundamentally altered by prolonged opioid or alcohol exposure, medication is not a shortcut around recovery—it is the clinical foundation that makes sustained recovery possible.
What is substitution therapy for heroin?
Substitution therapy—more accurately called opioid agonist therapy—works by replacing a short-acting, dangerous opioid like heroin or illicit fentanyl with a longer-acting, clinically managed medication that prevents withdrawal and reduces cravings without producing the euphoria associated with illicit use. The two primary medications used in this approach are methadone and buprenorphine. Methadone is a full opioid agonist administered in licensed treatment settings, typically as a daily oral dose. It occupies the same brain receptors that heroin targets, stabilizing the person's neurochemistry and eliminating the cycle of intoxication and withdrawal that drives compulsive use. Methadone has been used for over 50 years and has one of the strongest evidence bases of any addiction treatment modality. Buprenorphine—commonly known by the brand names Suboxone and Sublocade—is a partial opioid agonist, meaning it activates opioid receptors to a lesser degree than methadone or heroin. This ceiling effect makes buprenorphine safer in terms of overdose risk and allows it to be prescribed in a wider range of clinical settings, including inpatient rehab programs in Charlotte. Both medications are most effective when combined with behavioral therapy. The medication addresses the neurobiological component of opioid use disorder—the physical cravings and withdrawal that make abstinence without pharmacological support extraordinarily difficult—while therapy addresses the psychological, behavioral, and social dimensions. The term 'substitution' is falling out of clinical favor because it implies simply swapping one drug for another, which misrepresents the therapeutic purpose. These medications restore normal brain function rather than creating a new form of dependence.
Methadone versus buprenorphine: key differences
Methadone requires daily attendance at a licensed clinic for dosing, which provides structure but limits flexibility. It is generally preferred for individuals with severe, long-standing opioid use disorders who have not responded to buprenorphine. Buprenorphine can be prescribed by qualified physicians in an inpatient or outpatient setting, offering greater flexibility and privacy. The injectable form, Sublocade, provides a month-long dose in a single injection, eliminating the need for daily medication management. The choice between these medications in Charlotte depends on the individual's clinical severity, treatment history, and personal preferences.
What is heroin assisted treatment?
Heroin-assisted treatment—formally known as supervised injectable opioid agonist therapy or pharmaceutical-grade diacetylmorphine treatment—is a protocol used in several countries including Canada, Switzerland, Germany, and the United Kingdom for individuals with severe opioid use disorders who have not responded to standard MAT with methadone or buprenorphine. In these programs, medical-grade heroin (diacetylmorphine) is administered under strict clinical supervision, typically two to three times daily in a healthcare facility. This approach is not available in the United States. No program in Charlotte or anywhere in North Carolina offers heroin-assisted treatment, and it is not approved by the FDA. The question is worth addressing because it reflects a growing public awareness that some individuals with opioid use disorders do not achieve stability through existing treatment options, and the search for effective alternatives is ongoing. In Charlotte, the closest analogue to the clinical intent behind heroin-assisted treatment is high-dose methadone maintenance or the use of injectable buprenorphine (Sublocade) for individuals who have not succeeded with oral formulations. These approaches provide sustained opioid receptor stabilization without the risks associated with illicit drug use—contamination with fentanyl analogs, unpredictable potency, and the behavioral patterns associated with obtaining street drugs. For individuals in Charlotte whose prior treatment attempts have not produced sustained recovery, the conversation should focus on optimizing the available evidence-based options—adjusting medication types and doses, increasing therapeutic intensity through inpatient treatment, and addressing co-occurring conditions that may be undermining previous treatment efforts.
Evidence-based alternatives available in Charlotte
Charlotte inpatient programs offer the full range of FDA-approved MAT options: oral buprenorphine (Suboxone), injectable buprenorphine (Sublocade), naltrexone (Vivitrol) for opioid and alcohol use disorders, and referral to licensed methadone clinics for individuals who require full agonist therapy. Combining any of these medications with 30 to 90 days of residential treatment and structured aftercare represents the highest-intensity treatment pathway available in the United States. For individuals who have cycled through multiple treatment episodes, this combination approach offers the best evidence for sustained stabilization.
What do they give drug addicts in rehab?
The medications administered during inpatient treatment in Charlotte depend entirely on the substance involved and the individual's clinical presentation. For opioid use disorders—including heroin and fentanyl dependence—buprenorphine is the most commonly initiated medication during the inpatient phase. It reduces cravings, prevents withdrawal symptoms, and allows the person to engage meaningfully in therapy rather than spending their days managing physical discomfort. Naltrexone, available as a monthly injection under the brand name Vivitrol, is another option typically initiated toward the end of the inpatient stay or during the transition to outpatient care. Unlike buprenorphine, naltrexone is an opioid antagonist—it blocks opioid receptors entirely, preventing any effect from opioid use. This makes it a strong choice for individuals who are committed to complete abstinence from opioids. For alcohol use disorders, several medications are evidence-based. Naltrexone reduces the reinforcing effects of alcohol, making drinking less pleasurable and reducing the urge to drink. Acamprosate helps stabilize brain chemistry disrupted by chronic alcohol use and may reduce cravings in the months following detox. Disulfiram causes unpleasant physical reactions when alcohol is consumed, serving as a behavioral deterrent. Beyond addiction-specific medications, inpatient programs in Charlotte also prescribe psychiatric medications as needed. Antidepressants, mood stabilizers, anti-anxiety medications, and sleep aids may all be part of an individual's treatment plan when co-occurring mental health conditions are present. Every medication is prescribed by a physician, monitored by clinical staff, and adjusted based on the person's response throughout their stay.
Addressing stigma around medication in recovery
A persistent misconception holds that using medication during recovery means a person is not truly sober. This view is not supported by clinical evidence. Major medical organizations—including the American Society of Addiction Medicine and the National Institute on Drug Abuse—recognize MAT as a first-line treatment for opioid use disorders. Medications like buprenorphine and naltrexone do not produce intoxication when taken as prescribed. They restore normal brain function that has been disrupted by chronic substance exposure. In Charlotte's recovery community, acceptance of MAT has grown significantly as the opioid crisis has made clear that abstinence-only approaches do not serve every individual.
Questions about treatment options in Charlotte?
📞 704-207-0877 — Call AnytimeFrequently Asked Questions
Is MAT just replacing one drug with another?
No. This is the most common misconception about medication-assisted treatment. Medications like buprenorphine and naltrexone do not produce the euphoria, impaired judgment, or compulsive use patterns associated with illicit opioid use. They stabilize brain chemistry that has been fundamentally altered by chronic substance exposure, allowing the person to think clearly, engage in therapy, and function in daily life. The American Medical Association, the World Health Organization, and every major addiction medicine body recognize MAT as an evidence-based, first-line treatment—not a substitute addiction.
How long do people stay on MAT medications?
The duration of MAT is individualized. Some people use medications like buprenorphine for months as they stabilize and build recovery skills, then taper under medical supervision. Others benefit from longer-term or indefinite medication management—particularly those with severe or long-standing opioid use disorders. Research shows that longer durations of MAT are associated with better outcomes, and discontinuing medication prematurely is one of the strongest predictors of return to use. The decision about duration is made collaboratively between the individual and their treatment team in Charlotte.
Can I start MAT during inpatient rehab in Charlotte?
Yes. Many inpatient programs in Charlotte initiate MAT during the residential phase of treatment. Starting medication in a supervised inpatient environment allows the clinical team to monitor response, adjust dosing, and address side effects in real time. It also ensures a seamless transition to outpatient MAT management upon discharge. Individuals who begin MAT during inpatient care and continue it after discharge have significantly better retention in treatment and lower rates of return to use compared to those who discontinue medication at the point of discharge.
Does PPO insurance cover medication-assisted treatment?
Most PPO insurance plans cover MAT as part of substance use disorder treatment. The Mental Health Parity and Addiction Equity Act requires insurers to cover addiction treatment at parity with other medical conditions, and MAT medications are classified as essential health benefits under most plans. Coverage typically includes the medication itself, the clinical visits associated with prescribing and monitoring, and the behavioral therapy that accompanies MAT. Call (704) 207-0877 to verify your specific PPO benefits and understand any applicable copays or formulary requirements.
What is the difference between Suboxone and Vivitrol?
Suboxone (buprenorphine/naloxone) is a partial opioid agonist taken daily as a sublingual film or tablet. It reduces cravings and prevents withdrawal by partially activating opioid receptors. Vivitrol (naltrexone) is an opioid antagonist administered as a monthly injection that blocks opioid receptors entirely. Suboxone can be started during active withdrawal and is often used during early detox. Vivitrol requires seven to ten days of opioid abstinence before initiation, making it more commonly started later in treatment. Both are effective—the choice depends on clinical presentation, patient preference, and treatment goals.